LC-MS/MS method assay for simultaneous determination of the pretomanid and pyrazinamide in rat plasma by LC-MS/MS: Assessment of pharmacokinetic drug-drug interaction study

• Autorzy: Huang Tao , Wang Li , Wang Fang , Shen Xin , Wang Libin

Identyfikatory

DOI

10.1556/1326.2022.01087

• Języki publikacji: EN

Abstrakty

EN

In the present study, an LC-MS/MS method allowing to quantify pretomanid and pyrazinamide simultaneously in rat plasma was developed. Chromatographic separation was achieved on an Agilent Eclipse plus C18 column (100 mm × 2.1 mm, 3.5 μm; Agilent, USA) and maintained at 30 °C. Multiple reaction monitoring (MRM) using positive-ion ESI mode to monitor ion transitions of m/z 360.1 → m/z 175.1 for pretomanid, m/z 124.1 → m/z 81.0 for pyrazinamide, m/z 172.1 → m/z 128.1 for metronidazole (IS). The calibration curves showed good linear relationships over the concentration range of 50–7,500 ng mL⁻¹ for pretomanid and 500–75,000 ng mL⁻¹ for pyrazinamide. The precision and accuracy were below 15% and within ±15% of the nominal concentrations, respectively. The selectivity, recovery and matrix effect of this method were all within acceptable limits of bioanalytics. The method was applied to the analysis of plasma samples from pharmacokinetic studies in rats. The results show that the main pharmacokinetic parameters of pyrazinamide, namely, T _max , t_1/2, and AUC_(0–t), decreased in the combined group than in the alone group.

Słowa kluczowe

EN

pretomanid; pyrazinamide; drug-drug interaction; LC-MS/MS

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2024
• Tom: Vol. 36, no. 1
• Strony: 7--13
• Opis fizyczny: Bibliogr. 19 poz., tab., wykr.

Twórcy

autor

Huang Tao

• Medical School, Huanghe Science and Technology University, Zhengzhou, Henan Province 450063, PR China

autor

Wang Li

• Medical School, Huanghe Science and Technology University, Zhengzhou, Henan Province 450063, PR China

autor

Wang Fang

• School of Medicine, Shaanxi Energy Institute, Xianyang, Shaanxi Province 712000, PR China

autor

Shen Xin

• Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, PR China

• https://orcid.org/0000-0001-6766-001X

autor

Wang Libin

• Medical School, Huanghe Science and Technology University, Zhengzhou, Henan Province 450063, PR China
• School of Medicine, Shaanxi Energy Institute, Xianyang, Shaanxi Province 712000, PR China

• https://orcid.org/0000-0002-1216-2352

Bibliografia

• 1. Kharwadkar, S.; Attanayake, V.; Duncan, J.; Navaratne, N.; Benson, J. The impact of climate change on the risk factors for tuberculosis: a systematic review. Environ. Res. 2022, 212, 113436.
• 2. Feng, Q.; Hu, X.; Zhao, J.; Huang, J.; Liu, L. Female genital tuberculosis presented with primary infertility and persistent CA-125 elevation: a case report. Ann. Med. Surg. 2022, 78, 103683.
• 3. Stewart, G. R.; Robertson, B. D.; Young, D. B. Tuberculosis: a problem with persistence. Nat. Rev. Microbiol. 2003, 1, 97–105.
• 4. Nachega, J. B.; Chaisson, R. E. Tuberculosis drug resistance: a global threat. Clin. Infect. Dis. 2003, 36, S24–30.
• 5. Sun, J.; Champion, P. A.; Bigi, F. Editorial: cellular and molecular echanisms of Mycobacterium tuberculosis virulence. Front. Cell Infect. Microbiol. 2019, 9.
• 6. Cole, S. T. Mechanisms of drug resistance in Mycobacterium tuberculosis. Front Biosci. 2009, 191, 975–94.
• 7. WHO Global tuberculosis report, 2019. https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf? ua=1.
• 8. Haydel, S. E. Extensively drug-resistant tuberculosis: a sign of the times and an impetus for antimicrobial discovery. Pharmaceuticals 2010, 3, 2268–90.
• 9. Prasad, R. Multidrug and extensively drug-resistant TB (M/XDR-TB): problems and solutions. Indian J. Tuberc. 2010, 57, 180–91.
• 10. Stancil, S. L.; Mirzayev, F.; Abdel-Rahman, S. M. Profiling pretomanid as a therapeutic option for TB infection: evidence to date. Drug Des. Develop. Ther. 2021, 15, 2815–30.
• 11. Bahuguna, A.; Rawat, D. S. An overview of new antitubercular drugs, drug candidates, and their targets. Med. Res. Rev. 2020, 40, 263–92.
• 12. Kadura, S.; King, N.; Nakhoul, M.; Zhu, H.; Theron, G.; Köser, C. U.; Farhat, M. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. J. Antimicrob. Chemother. 2020, 75, 2031–43.
• 13. Stehr, M.; Elamin, A.; Singh, M. Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria: expert Review of Anti-infective Therapy. Expert Rev. Anti-infective Ther. 2015, 13(5).
• 14. Njire, M.; Tan, Y.; Mugweru, J.; Wang, C.; Guo, J.; Yew, W.; Tan, S.; Zhang, T. Pyrazinamide resistance in Mycobacterium tuberculosis: review and update. Adv. Med. Sci. 2016, 61, 63–71.
• 15. Younossian, A. B.; Rochat, T.; Ketterer, J.-P.; Wacker, J.; Janssens, J.-P. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur. Respir. J. 2005, 26, 462–4.
• 16. Diacon, A. H.; Dawson, R.; Groote-Bidlingmaier, F. V.; Symons, G.; Venter, A.; Donald, P. R.; Niekerk, C. V.; Everitt, D.; Hutchings, J.; Burger, D. A. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am. J. Respir. Crit. Care Med. 2015, 191, 943.
• 17. Wang, L.; Xu, Y.; Liang, L.; Diao, C.; Liu, X.; Zhang, J.; Zhang, S. LC-MS/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study. J. Pharm. Biomed. Anal. 2014, 97, 1–8.
• 18. Bratkowska, D.; Shobo, A.; Singh, S.; Bester, L.A.; Kruger, H. G.; Maguire, G.; Govender, T. Determination of the antitubercular drug PA-824 in rat plasma, lung and brain tissues by liquid chromatography tandem mass spectrometry: application to a pharmacokinetic study. J. Chromatogr. B 2015, 988, 187–94.
• 19. Sanyal, M.; Shrivastav, S. P.; Shah, V. J.; Sharma, P.; Priyanka, A. An improved LC-MS/MS method for the simultaneous determination of pyrazinamide, pyrazinoic acid and 5-hydroxy pyrazinoic acid in human plasma for a pharmacokinetic study. J. Chromatogr. B. Anal. Tech. Biomed. Life Sci. 2016.